According to a recently published report, using a triple agonist, designed to combine FXR activation with dual peroxisome-proliferator-activated receptor (PPAR α and δ) activation, in diet-induced mouse models of NASH, produced superior outcomes compared to mono-targeted agents [103]. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.